RecombinantRabMAb

Recombinant PE Anti-IRF5 antibody [EPR17067] (ab212239)

Submit a review Submit a question References (1)
Flow Cytometry - PE Anti-IRF5 antibody [EPR17067] (ab212239)
  • PE Anti-IRF5 antibody [EPR17067] (ab212239)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • PE Rabbit monoclonal [EPR17067] to IRF5
  • Suitable for: Flow Cyt
  • Reacts with: Mouse
  • Conjugation: PE. Ex: 488nm, Em: 575nm

Overview

  • Product name

    PE Anti-IRF5 antibody [EPR17067]
    See all IRF5 primary antibodies

  • Description

    PE Rabbit monoclonal [EPR17067] to IRF5

  • Host species

    Rabbit

  • Conjugation

    PE. Ex: 488nm, Em: 575nm

  • Tested applications

    Suitable for: Flow Cytmore details

  • Species reactivity

    Reacts with: Mouse
    Predicted to work with: Rat, Human

  • Immunogen

    Recombinant fragment within Human IRF5 aa 1-200. The exact sequence is proprietary.
    Database link: Q13568-4

  • Positive control

    • Flow Cytometry: RAW264.7 cells

  • General notes

     

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

    Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

    We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

    In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

    We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

    Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

    Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Applications

Our Abpromise guarantee covers the use of ab212239 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt 1/1000.

The cellular localisation of this product has been verified in ICC/IF.

Target

  • Involvement in disease

    Genetic variations in IRF5 are associated with susceptibility to inflammatory bowel disease type 14 (IBD14) [MIM:612245]. IBD14 is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.
    Genetic variations in IRF5 are associated with susceptibility to systemic lupus erythematosus type 10 (SLEB10) [MIM:612251]. Systemic lupus erythematosus (SLE) is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. It is thought to represent a failure of the regulatory mechanisms of the autoimmune system.
    Genetic variations in IRF5 are a cause of susceptibility to rheumatoid arthritis (RA) [MIM:180300]. It is a systemic inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.

  • Sequence similarities

    Belongs to the IRF family.
    Contains 1 IRF tryptophan pentad repeat DNA-binding domain.

  • Cellular localization

    Nucleus.
  • Information by UniProt

  • Database links

    see all

  • Alternative names

    • Interferon regulatory factor 5 antibody
    • Interferon regulatory factor 5 bone marrow variant antibody
    • IRF 5 antibody
    • IRF-5 antibody
    • Irf5 antibody
    • IRF5_HUMAN antibody
    • SLEB10 antibody
    see all

Images

  • Flow Cytometry - PE Anti-IRF5 antibody [EPR17067] (ab212239)
    Flow Cytometry - PE Anti-IRF5 antibody [EPR17067] (ab212239)

    Overlay histogram showing RAW264.7 cells stained with ab212239 (red line). The cells were fixed with 4% formaldehyde and then permeabilized with 0.1% PBS-Triton X-100 for 15 min. The cells were then incubated in 1x PBS / 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (ab212239, 1/1000 dilution) for 30 min at 22°C. Isotype control antibody (black line) was rabbit IgG (monoclonal) Phycoerythrin (ab209478) used at the same concentration and conditions as the primary antibody. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 50mW Yellow/Green laser (561nm) and 586/15 bandpass filter. 

    This antibody gave a positive signal in RAW264.7 cells fixed with 80% methanol (5 min), permeabilized with 0.1% PBS-Triton X-100 for 15 min used under the same conditions.

  • PE Anti-IRF5 antibody [EPR17067] (ab212239)
    PE Anti-IRF5 antibody [EPR17067] (ab212239)

References (1)

Publishing research using ab212239? Please let us know so that we can cite the reference in this datasheet.

ab212239 has been referenced in 1 publication.

  • Bachus H  et al. Impaired Tumor-Necrosis-Factor-a-driven Dendritic Cell Activation Limits Lipopolysaccharide-Induced Protection from Allergic Inflammation in Infants. Immunity 50:225-240.e4 (2019). PubMed: 30635238

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

There are currently no Customer reviews or Questions for ab212239.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com